Please login to the form below
Britain
This page shows the latest Britain news and features for those working in and with pharma, biotech and healthcare.
UCB's bimekizumab shows continued improvement in hidradenitis suppurativa patients
Bimekizumab is already approved in the EU and Great Britain for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Latest news
-
AstraZeneca’s heart failure treatment approved for expanded use in EU
As well as this most recent EU approval, Forixga has also been approved in Great Britain, Japan and Turkey to extend the HF indication to include patients across the full spectrum
-
BeiGene’s Brukinsa granted two new marketing authorisations by MHRA
Dr Renata Walewska, Department of Haematology, University Hospitals Dorset said: “The authorisation of Brukinsa for MZL and CLL in Great Britain is a significant step forward for eligible patients and their
-
Pfizer completes acquisition of Global Blood Therapeutics for $5.4bn
older. The drug is also approved in the EU, the UAE, Oman and Britain.
-
AstraZeneca’s Tezspire receives MHRA approval as add-on treatment for severe asthma
Tezspire demonstrated reduced annualised rate of asthma exacerbations. AstraZeneca’s (AZ) Tezspire (tezepelumab) has been granted marketing authorisation in Great Britain by the Medicines and Healthcare products Regulatory Agency (MHRA) for
-
Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
The marketing authorisation in Britain is specifically for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with ... Locametz (gozetotide)
More from news
Approximately 3 fully matching, plus 258 partially matching documents found.
Latest Intelligence
-
Setting up for success in a post-Brexit, post-pandemic Britain
Creating a new biotech affiliate and seeking marketing authorisation for a new drug in the UK during a pandemic
-
Route 66: can remote working put two-thirds of us back on the road to engaged employment?
With a recent PwC poll showing that more than 20 of Britain’s biggest firms have no plans for employees to come back to the office, the need to evolve employee
-
Pharma funding and M&A in 2020
So in 2020, as much as investors will be paying attention to noises from Boston, the San Francisco Bay Area, Britain, yes Britain, and even Brussels, I suspect they’ll also
-
The transatlantic opioid crisis
Meanwhile, in Britain. A Public Health England enquiry revealed the scale of opioid consumption in the UK in September 2019, with prescriptions now being handed out to one in eight of
-
25 Women Leaders in UK Healthcare (part 2)
She became Britain’s youngest hospital leader when she was appointed chief executive of Birmingham Children’s Hospital in 2007 at the age of 32, subsequently helping it win Provider Trust
More from intelligence
Approximately 0 fully matching, plus 23 partially matching documents found.
Latest appointments
-
UCB appoints new managing director of Britain and Ireland
Steve Turley joins from Lundbeck
-
Gopa Mitra retires from PAGB
She steps down after 34 years at organisation. Gopa Mitra is to retire from the Proprietary Association of Great Britain (PAGB) after 34 years at the organisation.
-
GSK's Lawson elected PAGB president
The Proprietary Association of Great Britain (PAGB), which represents OTC companies in the UK, has elected Carlton Lawson of GlaxoSmithKline (GSK) as its new president.
-
MHRA announces senior appointment
McGuire's career has also seen him involved with a number of professional bodies, including the Association of Anaesthetists of Great Britain and Ireland, the Royal College of Anaesthetists and the
-
Steve Arnold joins UCB from Gilead
Appointed managing director for the British and Irish Isles. UCB has appointed Steve Arnold as managing director for Great Britain and Ireland.
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
A new 10-year cancer plan: Will the government be able to deliver what the sector needs?
Britain has a strong track record of setting out plans for cancer services, with the most recent substantive strategy published in 2015 (Achieving world-class cancer outcomes: a strategy for England
-
IWD2021: #ChooseToChallenge Interview with Dennis O’Brien, Lucid Group CEO
I learnt so much from Melanie Lee, who was Director of R&D at Celltech, Britain’s most successful biotech.
-
Let's be ambitious for patients and life sciences investment in Global Britain
In post-Brexit ‘Global Britain’, Government wants a rejuvenated MHRA to help the UK become a global early launch market. ... sciences investment for the new Global Britain.
-
HOW INNOVATION IS RESHAPING THE NORTH EAST LIFE SCIENCES LANDSCAPE
In a post Brexit Britain where the UK’s future trading relationship with the EU remains uncertain, adopting more innovative business practices will be crucial to keeping the sector globally competitive. ... We must ensure the North East’s
-
The fight against COVID-19 needs to have diversity at the heart of its strategy
In recognition of this, the #CharitySoWhite campaign has demanded action over the disproportionate impact of the virus on Britain’s minorities.
More from PMHub
Approximately 0 fully matching, plus 24 partially matching documents found.
Subscribe to our email news alerts
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- FDA external report recommends actions to address US opioid crisis
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Congress is in session – how companies are boosting their impact and engagement
- AstraZeneca announces major expansion of Canadian research footprint
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
